[Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study]

Rev Esp Cir Ortop Traumatol. 2013 Jan-Feb;57(1):53-60. doi: 10.1016/j.recot.2012.10.009. Epub 2012 Dec 5.
[Article in Spanish]

Abstract

Introduction: Prolongation of drug-based thromboembolism prophylaxis after discharge from hospital is clearly recommended following total hip and knee replacement. The aim of this study was to evaluate and compare adherence to and satisfaction with outpatient thromboembolism prophylaxis (by injection and oral) under routine clinical practice conditions.

Material and method: We analysed two consecutive cohorts of patients (480 and 366, respectively) who had undergone total hip or knee replacement surgery in 120 Spanish hospitals, and were prescribed outpatient thromboembolism prophylaxis, by injection and orally, respectively. Information on adherence to and satisfaction with both treatments, sociodemographic data and treatment compliance was collected using specific questionnaires.

Results: The drop-out rate (9.49 vs. 4.14%), general satisfaction (37 vs. 83.38%), and the TSQM satisfaction scale were better in the oral prophylaxis cohort and, although the differences between the two routes of administration were not significant, treatment compliance was also better in the oral cohort (Morisky-Green test: 53.49 vs. 59.05%).

Conclusions: Adherence to and satisfaction with the oral thromboembolism prophylaxis were better than for prophylaxis by injection in the context of outpatient prolongation. Nevertheless, suboptimal treatment compliance was found in both cohorts, which could result in lack of efficacy of the prophylaxis. Both patients and doctors have to be made aware of the importance of post-discharge extension of thromboprophylaxis in orthopaedic surgery with high thrombotic risk. Moreover, strategies should be developed to encourage compliance.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage*
  • Anticoagulants / therapeutic use
  • Arthroplasty, Replacement, Hip
  • Arthroplasty, Replacement, Knee
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / therapeutic use
  • Cohort Studies
  • Dabigatran
  • Female
  • Fondaparinux
  • Heparin, Low-Molecular-Weight / administration & dosage
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Injections, Subcutaneous
  • Male
  • Medication Adherence / statistics & numerical data*
  • Middle Aged
  • Morpholines / administration & dosage
  • Morpholines / therapeutic use
  • Patient Satisfaction / statistics & numerical data*
  • Polysaccharides / administration & dosage
  • Polysaccharides / therapeutic use
  • Postoperative Care / methods*
  • Postoperative Complications / prevention & control*
  • Pulmonary Embolism / etiology
  • Pulmonary Embolism / prevention & control
  • Rivaroxaban
  • Spain
  • Surveys and Questionnaires
  • Thiophenes / administration & dosage
  • Thiophenes / therapeutic use
  • Treatment Outcome
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control*
  • Venous Thrombosis / etiology
  • Venous Thrombosis / prevention & control
  • beta-Alanine / administration & dosage
  • beta-Alanine / analogs & derivatives
  • beta-Alanine / therapeutic use

Substances

  • Anticoagulants
  • Benzimidazoles
  • Heparin, Low-Molecular-Weight
  • Morpholines
  • Polysaccharides
  • Thiophenes
  • beta-Alanine
  • Rivaroxaban
  • Dabigatran
  • Fondaparinux